PAGE 1
HOUSE BILL 424

J1, J5 (5lr2044)
ENROLLED BILL
— Health and Government Operations/Finance —
Introduced by Delegates Cullison ~~and~~ ~~White~~ ~~Holland,~~ White Holland, Alston,
Bagnall, Bhandari, Guzzone, Hill, S. Johnson, Kaiser, Kerr, Lopez,
Martinez, Pena–Melnyk, Rosenberg, Taveras, Woods, and Woorman

Read and Examined by Proofreaders:

_______________________________________________
Proofreader.
_______________________________________________
Proofreader.

Sealed with the Great Seal and presented to the Governor, for his approval this

_______ day of _______________ at ________________________ o’clock, ________M.

______________________________________________
Speaker.

CHAPTER ______

1 AN ACT concerning

2 Prescription Drug Affordability Board – Authority ~~for~~ ~~Upper~~ ~~Payment~~ ~~Limits~~
3 and Stakeholder Council Membership
4 (Lowering Prescription Drug Costs for All Marylanders Now Act)

5 FOR the purpose of altering the membership of the Prescription Drug Affordability
6 Stakeholder Council; requiring the Prescription Drug Affordability Board, under
7 certain circumstances, to establish a process for setting upper payment limits for ~~all~~
8 purchases and payor reimbursements of prescription drug products in the State that
9 the Board determines have led or will lead to affordability challenges; authorizing
10 the Board to reconsider an upper payment limit for a drug that becomes a current
11 shortage; altering requirements related to the setting of upper payment limits by the
12 Board; requiring the Board to confer with the Maryland Medical Assistance Program
13 before establishing an upper payment limit that applies to the Program; prohibiting

EXPLANATION: CAPITALS LAW.INDICATE MATTER ADDED TO EXISTING
[Brackets] indicate matter deleted from existing law.
Underlining indicates amendments to bill.
~~Strike~~ ~~out~~ indicates matter stricken from the bill by amendment or deleted from the law by
amendment.
Italics indicate opposite chamber/conference committee amendments.*hb0424*

PAGE 2
2 HOUSE BILL 424

1 the Board from taking certain actions related to upper payment limits; and generally
2 relating to the Prescription Drug Affordability Board.

3 BY repealing and reenacting, with amendments,
4 Article – Health – General
5 Section 21–2C–01, 21–2C–04, 21–2C–13, and 21–2C–14
6 Annotated Code of Maryland
7 (2023 Replacement Volume and 2024 Supplement)

8 BY repealing and reenacting, without amendments,
9 Article – Health – General
10 Section 21–2C–09(c) and 21–2C–11(a)
11 Annotated Code of Maryland
12 (2023 Replacement Volume and 2024 Supplement)

13 BY adding to
14 Article – Health – General
15 Section 21–2C–09(d) and (e) and 21–2C–16
16 Annotated Code of Maryland
17 (2023 Replacement Volume and 2024 Supplement)

18 BY repealing
19 Article – Health – General
20 Section 21–2C–11(d) and 21–2C–16
21 Annotated Code of Maryland
22 (2023 Replacement Volume and 2024 Supplement)

23 ~~BY~~ ~~adding~~ ~~to~~
24 ~~Article~~ ~~–~~ ~~Health~~ ~~–~~ ~~General~~
25 ~~Section~~ ~~21–2C–16~~
26 ~~Annotated~~ ~~Code~~ ~~of~~ ~~Maryland~~
27 ~~(2023~~ ~~Replacement~~ ~~Volume~~ ~~and~~ ~~2024~~ ~~Supplement)~~

28 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
29 That the Laws of Maryland read as follows:

30 Article – Health – General

31 21–2C–01.

32 (a) In this subtitle the following words have the meanings indicated.

33 (b) “Biologic” means a drug that is produced or distributed in accordance with a
34 biologics license application approved under 42 C.F.R. § 447.502.

35 (c) “Biosimilar” means a drug that is produced or distributed in accordance with
36 a biologics license application approved under 42 U.S.C. § 262(k)(3).

PAGE 3
HOUSE BILL 424 3

1 (d) “Board” means the Prescription Drug Affordability Board.

2 (e) (1) “Brand name drug” means a drug that is produced or distributed in
3 accordance with an original new drug application approved under 21 U.S.C. § 355(c).

4 (2) “Brand name drug” does not include an authorized generic as defined
5 by 42 C.F.R. § 447.502.

(F) “CURRENT SHORTAGE” DRUG:6 MEANS A

(1) LISTED FOOD DRUG7 AS CURRENT ON THE FEDERAL AND
ADMINISTRATION’S DRUG SHORTAGE DATABASE;8 OR

(2) OTHERWISE BOARD9 DETERMINED BY THE TO BE IN SHORT
STATE.10 SUPPLY IN THE

[(f)] (G)11 “Generic drug” means:

12 (1) A retail drug that is marketed or distributed in accordance with an
13 abbreviated new drug application, approved under 21 U.S.C. § 355(j);

14 (2) An authorized generic as defined by 42 C.F.R. § 447.502; or

15 (3) A drug that entered the market before 1962 that was not originally
16 marketed under a new drug application.

[(g)] (H)17 “Manufacturer” means an entity that:

18 (1) (i) Engages in the manufacture of a prescription drug product; or

19 (ii) Enters into a lease with another manufacturer to market and
20 distribute a prescription drug product under the entity’s own name; and

21 (2) Sets or changes the wholesale acquisition cost of the prescription drug
22 product it manufactures or markets.

[(h)] (I)23 “Prescription drug product” means a brand name drug, a generic drug,
24 a biologic, or a biosimilar.

[(i)] (J)25 “Stakeholder Council” means the Prescription Drug Affordability
26 Stakeholder Council.

27 21–2C–04.

28 (a) There is a Prescription Drug Affordability Stakeholder Council.

PAGE 4
4 HOUSE BILL 424

1 (b) The purpose of the Stakeholder Council is to provide stakeholder input to assist
2 the Board in making decisions as required under this subtitle.

[26]3 (c) (1) The Stakeholder Council consists of members appointed in
4 accordance with this subsection.

5 (2) The Speaker of the House of Delegates shall appoint:

6 (i) One representative of generic drug corporations;

7 (ii) One representative of nonprofit insurance carriers;

8 (iii) One representative of a statewide health care advocacy coalition;

9 (iv) One representative of a statewide advocacy organization for
10 seniors;

11 (v) One representative of a statewide organization for diverse
12 communities;

13 (vi) One representative of a labor union;

ONE14 (vii) COMMUNITY;REPRESENTATIVE OF THE RARE DISEASE

15 (VIII) One health services researcher specializing in prescription drugs;
16 and

[(viii)]17 (IX) One public member at the discretion of the Speaker of the
18 House of Delegates.

19 (3) The President of the Senate shall appoint:

20 (i) One representative of brand name drug corporations;

21 (ii) One representative of physicians;

22 (iii) One representative of nurses;

23 (iv) One representative of hospitals;

24 (v) One representative of dentists;

ONE ONCOLOGISTS;25 (vi) REPRESENTATIVE OF

(VII)26 One representative of managed care organizations;

PAGE 5
HOUSE BILL 424 5

[(vii)] (VIII)1 One representative of the Department of Budget and
2 Management;

[(viii)] (IX)3 One clinical researcher; and

[(ix)] (X)4 One public member at the discretion of the President of the
5 Senate.

6 (4) The Governor shall appoint:

7 (i) One representative of brand name drug corporations;

8 (ii) One representative of generic drug corporations;

9 (iii) One representative of biotechnology companies;

10 (iv) One representative of for–profit health insurance carriers;

11 (v) One representative of employers;

12 (vi) One representative of pharmacy benefits managers;

13 (vii) One representative of pharmacists;

[and]14 (viii) One pharmacologist;

ONE15 (ix) REPRESENTATIVE OF A PATIENT ADVOCACY
ORGANIZATION;16 AND

(X)17 One public member at the discretion of the Governor.

18 (5) Collectively, the members of the Stakeholder Council shall have
19 knowledge of the following:

20 (i) The pharmaceutical business model;

21 (ii) Supply chain business models;

22 (iii) The practice of medicine or clinical training;

23 (iv) Consumer or patient perspectives;

24 (v) Health care costs trends and drivers;

25 (vi) Clinical and health services research; or

PAGE 6
6 HOUSE BILL 424

1 (vii) The State’s health care marketplace.

2 (6) To the extent practicable and consistent with federal and State law, the
3 membership of the Stakeholder Council shall reflect the racial, ethnic, and gender diversity
4 of the State.

5 (7) From among the membership of the Stakeholder Council, the Board
6 chair shall appoint two members to be cochairs of the Stakeholder Council.

7 (d) (1) The term of a member is 3 years.

8 (2) The initial members of the Stakeholder Council shall serve staggered
9 terms as required by the terms provided for members on October 1, 2019.

10 (e) A member of the Stakeholder Council:

11 (1) May not receive compensation as a member of the Stakeholder Council;
12 but

13 (2) Is entitled to reimbursement for expenses under the Standard State
14 Travel Regulations, as provided in the State budget.

15 21–2C–09.

16 (c) On or before December 31, 2020, and each December 31 thereafter, the Board
17 shall submit to the Senate Finance Committee and the House Health and Government
18 Operations Committee, in accordance with § 2–1257 of the State Government Article, a
19 report that includes:

20 (1) Price trends for prescription drug products;

21 (2) The number of prescription drug products that were subject to Board
22 review and the results of the review; and

23 (3) Any recommendations the Board may have on further legislation needed
24 to make prescription drug products more affordable in the State.

(D) IF BOARD LIMIT,25 THE SETS A NEW UPPER PAYMENT TO THE EXTENT
PRACTICABLE, BOARD26 THE SHALL INCLUDE IN THE FIRST REPORT THAT IS
(C)27 REQUIRED UNDER SUBSECTION OF THIS SECTION AFTER THE UPPER PAYMENT
128 LIMIT HAS BEEN IN EFFECT FOR YEAR INFORMATION ON THE EFFECTS OF THE
LIMIT, DATA, FOLLOWING:29 UPPER PAYMENT BASED ON AVAILABLE TIMELY FOR THE

PAGE 7
HOUSE BILL 424 7

(1) PATIENT OUT–OF–POCKET1 COSTS INCLUDING WHETHER THE
2 UPPER PAYMENT LIMIT WAS ASSOCIATED WITH INCREASES OR DECREASES IN WHAT
PRODUCTS;3 PATIENTS PAY FOR PRESCRIPTION DRUG

(2) PATIENT PREMIUMS,4 HEALTH INSURANCE INCLUDING WHETHER
5 THE UPPER PAYMENT LIMIT IS ASSOCIATED WITH INCREASES OR DECREASES IN
PATIENTS;6 HEALTH INSURANCE COSTS FOR

(3) PHARMACIES STATE,7 OPERATING IN THE INCLUDING THE IMPACT
8 ON REIMBURSEMENT RATES AND FINANCIAL VIABILITY OF RETAIL AND
PHARMACIES;9 INDEPENDENT

(4) PATIENT FORMULARIES,10 HEALTH INSURANCE INCLUDING
11 WHETHER THE PRESCRIPTION DRUG PRODUCT SUBJECT TO THE UPPER PAYMENT
FORMULARIES;12 LIMIT REMAINED ON

(5) PROVIDER–ADMINISTERED13 MEDICATIONS SUBJECT TO THE
LIMIT,14 UPPER PAYMENT INCLUDING WHETHER PROVIDERS WERE ABLE TO ACQUIRE
15 THE PRESCRIPTION DRUG PRODUCT SUBJECT TO THE UPPER PAYMENT LIMIT AT A
16 RATE TO ACCOUNT FOR ACQUISITION COSTS AND WHETHER THERE WAS AN IMPACT
REIMBURSEMENT;17 ON PROVIDER

(6) PATIENT18 ACCESS TO THE PRESCRIPTION DRUG PRODUCT
LIMIT, INCLUDE:19 SUBJECT TO THE UPPER PAYMENT WHICH MAY

(I) WHETHER20 PRESCRIPTION DRUG PRODUCT SHORTAGES OR
21 OTHER SUPPLY DISRUPTIONS OCCURRED AFTER THE UPPER PAYMENT LIMIT TOOK
EFFECT;22

(II) WHETHER23 FORMULARY PLACEMENT OR PLAN DESIGN
24 CHANGES MADE THE PRESCRIPTION DRUG PRODUCT SUBJECT TO THE UPPER LIMIT
ACCESS,25 MORE DIFFICULT FOR PATIENTS TO INCLUDING IF INSURANCE PLANS
26 PREFERRED A PRESCRIPTION DRUG PRODUCT WITHOUT AN UPPER PAYMENT LIMIT
LIMIT;27 OVER A PRESCRIPTION DRUG PRODUCT SUBJECT TO AN UPPER PAYMENT

(III) WHETHER28 THE DISTRIBUTION AND DELIVERY OF SPECIALTY
OUT–OF–STATE PROVIDERS,29 OR RARE DISEASE MEDICATIONS FROM PHARMACIES TO
PHARMACIES, IMPACTED;30 OR PATIENTS WAS

(IV) WHETHER COLOR,31 PATIENTS IN COMMUNITIES OF PATIENTS
WOMEN, DISEASE,32 WHO ARE PATIENTS WITH A RARE OR PATIENTS IN RURAL AREAS
CHALLENGES;33 EXPERIENCED DISPROPORTIONATE ACCESS AND

PAGE 8
8 HOUSE BILL 424

(V) WHETHER1 COST DIFFERENCES AS A RESULT OF THE UPPER
PATIENTS, PHARMACIES, AND,2 PAYMENT LIMIT AFFECTED OR PROVIDERS IF THE
COSTS,3 COST DIFFERENCE RESULTED IN AN INCREASE IN WHO WAS ULTIMATELY
COST;4 RESPONSIBLE FOR BEARING THE INCREASED

(7) COVERED 340B5 ENTITY PROVIDERS PARTICIPATING IN THE DRUG
PROGRAM,6 DISCOUNT INCLUDING THE IMPACT OF THE UPPER PAYMENT LIMIT ON
PHARMACIES;7 THE OPERATIONS OF THE PROVIDERS AND THEIR CONTRACTED AND

(8) THE STATE,8 BIOTECHNOLOGY INDUSTRY IN THE INCLUDING THE
DEVELOPMENT, INVESTMENT,9 IMPACT ON PHARMACEUTICAL RESEARCH AND AND
GROWTH.10 JOB

(E) (1) THE BOARD11 MAY REQUEST INFORMATION NECESSARY TO
(C) (D)12 COMPLETE THE REPORT REQUIRED UNDER SUBSECTIONS AND OF THIS
ENTITY.13 SECTION FROM AN AFFECTED

(2) THE14 ENTITY FROM WHICH INFORMATION WAS REQUESTED UNDER
(1)15 PARAGRAPH OF THIS SUBSECTION SHALL MAKE A GOOD FAITH EFFORT TO
INFORMATION.16 PROVIDE THE REQUESTED

17 21–2C–11.

18 (a) In this section, “Fund” means the Prescription Drug Affordability Fund.

[(d)19 (1) The Board shall be established using special or general funds, which
20 shall be repaid to the State with the funds from the Fund.

21 (2) If the Board receives funding from the Maryland Health Care
22 Commission under paragraph (1) of this subsection, the Board shall repay the funds to the
2021.]23 Commission from the Fund over a 3–year period beginning June 1,

24 21–2C–13.

25 (a) If, under § 21–2C–07 of this subtitle, the Board finds that it is in the best
26 interest of the State to establish a process for setting upper payment limits for prescription
27 drug products that it determines have led or will lead to an affordability challenge, the
28 Board, in conjunction with the Stakeholder Council, shall draft a plan of action for
[that29 implementing the process includes the criteria the Board shall use to set upper
limits]30 payment SECTION.IN ACCORDANCE WITH THE REQUIREMENTS OF THIS

31 (b) The criteria for setting upper payment limits shall include consideration of:

32 (1) The cost of administering the prescription drug product;

PAGE 9
HOUSE BILL 424 9

[and]1 (2) The cost of delivering the prescription drug product to consumers;

(3) THE2 EFFECT THE UPPER PAYMENT LIMIT WILL HAVE ON
340B DRUGS;3 PROVIDERS OF

(4) FOR4 AN UPPER PAYMENT LIMIT ON A DRUG THAT IS DESIGNATED
CONDITION,5 AS A DRUG FOR A RARE DISEASE OR THE IMPACT OF THE UPPER
DISEASES;6 PAYMENT LIMIT ON PATIENTS WITH RARE AND

[(3)] ~~(4)~~ (5)7 Other relevant administrative costs related to the prescription
8 drug product.

[(c)9 The process for setting upper payment limits shall:

10 (1) Prohibit the application of an upper payment limit for a prescription
11 drug product that is on the federal Food and Drug Administration prescription drug
12 shortage list; and

13 (2) Require the Board to:

14 (i) Monitor the availability of any prescription drug product for
15 which it sets an upper payment limit; and

16 (ii) If there becomes a shortage of the prescription drug product in
limit.]17 the State, reconsider or suspend the upper payment

(C) (1) IF BOARD18 THE PREVIOUSLY SET AN UPPER PAYMENT LIMIT FOR A
SHORTAGE, BOARD19 DRUG THAT BECOMES A CURRENT THE MAY RECONSIDER THE
LIMIT.20 PREVIOUSLY SET UPPER PAYMENT

(2) THE BOARD NOT:21 MAY

(I) ~~ESTABLISH~~ APPLY22 A NEW UPPER PAYMENT LIMIT ~~FOR~~ TO A
SHORTAGE;23 DRUG IN A CURRENT

(II) ENFORCE24 AN UPPER PAYMENT LIMIT AGAINST PROVIDER
MEDICARE PART C PART25 OR PHARMACY REIMBURSEMENT REQUIREMENTS FOR OR
D PLANS;26 OR

(III) COUNT27 A PHARMACY DISPENSING FEE TOWARD OR
LIMIT.28 SUBJECT A PHARMACY DISPENSING FEE TO AN UPPER PAYMENT

PAGE 10
10 HOUSE BILL 424

1 (d) (1) If a plan of action is drafted under subsection (a) of this section, the
2 Board shall submit the plan of action to the Legislative Policy Committee of the General
3 Assembly, in accordance with § 2–1257 of the State Government Article, for its approval.

4 (2) The Legislative Policy Committee shall have 45 days to approve the
5 plan of action.

6 (3) If the Legislative Policy Committee does not approve the plan of action,
7 the Board shall submit the plan to the Governor and the Attorney General for approval.

8 (4) The Governor and the Attorney General shall have 45 days to approve
9 the plan of action.

10 (5) The Board may not set upper payment limits unless the plan is
11 approved, in accordance with this subsection, by:

12 (i) The Legislative Policy Committee; or

13 (ii) 1. The Governor; and

14 2. The Attorney General.

15 21–2C–14.

[(a) subtitle] IN16 If a plan of action is approved under § 21–2C–13(d) of this
LEGISLATIVE POLICY17 ACCORDANCE WITH THE PLAN OF ACTION APPROVED BY THE
COMMITTEE OCTOBER 22, 2024,18 the Board may set upper payment limitsON THROUGH
19 for prescription drug products that are:REGULATIONS

20 (1) Purchased or paid for by a unit of State or local government or an
21 organization on behalf of a unit of State or local government, including:

22 (i) State or county correctional facilities;

23 (ii) State hospitals; and

24 (iii) Health clinics at State institutions of higher education;

25 (2) Paid for through a health benefit plan on behalf of a unit of State or
26 local government, including a county, bicounty, or municipal employee health benefit plan;
27 or

28 (3) Purchased for or paid for by the Maryland State Medical Assistance
29 Program.

[(b)30 The upper payment limits set under subsection (a) of this section shall:

PAGE 11
HOUSE BILL 424 11

1 (1) Be for prescription drug products that have led or will lead to an
2 affordability challenge; and

3 (2) Be set in accordance with the criteria established in regulations
4 adopted by the Board.

5 (c) (1) The Board shall:

6 (i) Monitor the availability of any prescription drug product for
7 which it sets an upper payment limit; and

8 (ii) If there becomes a shortage of the prescription drug product in
9 the State, reconsider whether the upper payment limit should be suspended or altered.

10 (2) An upper payment limit set under subsection (a) of this section may not
11 be applied to a prescription drug product while the prescription drug product is on the
list.]12 federal Food and Drug Administration prescription drug shortage

[21–2C–16.13

14 On or before December 1, 2026, the Board, in consultation with the Stakeholder
15 Council, shall report to the Senate Finance Committee and the House Health and
16 Government Operations Committee, in accordance with § 2–1257 of the State Government
17 Article, on:

18 (1) The legality, obstacles, and benefits of setting upper payment limits on
19 all purchases and payor reimbursements of prescription drug products in the State; and

20 (2) Recommendations regarding whether the General Assembly should
21 pass legislation to expand the authority of the Board to set upper payment limits to all
State.]22 purchases and payor reimbursements of prescription drug products in the

21–2C–16.23

(A) (1) THE BOARD, STAKEHOLDER24 IN CONSULTATION WITH THE
COUNCIL, WHETHER,25 SHALL DETERMINE IN ADDITION TO SETTING UPPER PAYMENT
§ 21–2C–14 SUBTITLE,26 LIMITS IN ACCORDANCE WITH OF THIS IT IS IN THE BEST
STATE BOARD27 INTEREST OF THE FOR THE TO ESTABLISH A PROCESS FOR SETTING
28 UPPER PAYMENT LIMITS FOR ~~ALL~~ PURCHASES AND PAYOR REIMBURSEMENTS OF
STATE BOARD29 PRESCRIPTION DRUG PRODUCTS IN THE THAT THE DETERMINES
CHALLENGE.30 HAVE LED OR WILL LEAD TO AN AFFORDABILITY

(2) WHEN (1)31 MAKING A DETERMINATION UNDER PARAGRAPH OF
SUBSECTION, BOARD CONSIDER, APPLICABLE:32 THIS THE SHALL IF

PAGE 12
12 HOUSE BILL 424

(I) CONTRACT BOARD1 AND BUDGET DATA PROVIDED TO THE
STATE2 THAT DEMONSTRATES SAVINGS TO THE OR LOCAL GOVERNMENTS AS A
§ 21–2C–143 RESULT OF UPPER PAYMENT LIMITS SET IN ACCORDANCE WITH OF THIS
SUBTITLE;4

(II) SUCCESS5 OF SETTING UPPER PAYMENT LIMITS IN OTHER
STATES;6 AND

(III) EXPECTED MEDICARE MAXIMUM FAIR7 SAVINGS FROM
PRICES CENTERS MEDICARE MEDICAID SERVICES.8 SET BY THE FOR AND

(B) (1) IF BOARD9 THE MAKES AN AFFIRMATIVE DETERMINATION UNDER
(A) SECTION, BOARD,10 SUBSECTION OF THIS THE IN CONSULTATION WITH THE
STAKEHOLDER COUNCIL,11 SHALL ESTABLISH A PROCESS FOR SETTING UPPER
12 PAYMENT LIMITS FOR ~~ALL~~ PURCHASES AND PAYOR REIMBURSEMENTS OF
STATE BOARD13 PRESCRIPTION DRUG PRODUCTS IN THE THAT THE DETERMINES
CHALLENGE.14 HAVE LED OR WILL LEAD TO AN AFFORDABILITY

(2) THE (1)15 PROCESS ESTABLISHED UNDER PARAGRAPH OF THIS
SHALL:16 SUBSECTION

(I) TO APPROPRIATE,17 THE EXTENT USE THE PLAN OF ACTION
§ 21–2C–13(D) SUBTITLE;18 APPROVED UNDER OF THIS AND

(II) OTHERWISE19 COMPLY WITH THE REQUIREMENTS FOR
SUBTITLE.20 SETTING UPPER PAYMENT LIMITS ESTABLISHED UNDER THIS

(3) BEFORE21 ESTABLISHING AN UPPER PAYMENT LIMIT THAT APPLIES
MARYLAND MEDICAL ASSISTANCE PROGRAM, BOARD22 TO THE THE SHALL CONFER
MARYLAND MEDICAL ASSISTANCE PROGRAM23 WITH THE TO APPROVE THE
24 APPLICATION OF THE UPPER PAYMENT LIMIT BY ASSESSING WHETHER THE
WILL:25 PROPOSED UPPER PAYMENT LIMIT

(I) CONFLICT MEDICAID DRUG REBATES26 WITH THE
PROGRAM, COVERED OUTPATIENT DRUG RULE (CMS–2345–FC),27 THE OR ANY
APPLICABLE;28 OTHER FEDERAL REQUIREMENTS AS AND

(II) REQUIRE29 ADDITIONAL FUNDING TO BE ALLOCATED TO THE
MARYLAND MEDICAL ASSISTANCE PROGRAM BUDGET.30

31 SECTION 2. AND BE IT FURTHER ENACTED, That the Laws of Maryland read
32 as follows:

PAGE 13
HOUSE BILL 424 13

1 Article – Health – General

2 21–2C–16.

(C) (1) ~~IF~~ SUBJECT (2) SUBSECTION,3 TO PARAGRAPH OF THIS IF THE
BOARD (B) SECTION,4 ESTABLISHES A PROCESS UNDER SUBSECTION OF THIS THE
BOARD5 SHALL SET UPPER PAYMENT LIMITS FOR ~~ALL~~ PURCHASES AND PAYOR
STATE6 REIMBURSEMENTS OF PRESCRIPTION DRUG PRODUCTS IN THE IN
PROCESS.7 ACCORDANCE WITH THE

(2) THIS TO:8 SUBSECTION DOES NOT APPLY WITH RESPECT

(I) PAYOR MEDICARE PART C9 REIMBURSEMENTS UNDER AND
D PLANS;10

(II) PURCHASES 340B DRUG PRICING11 UNDER THE FEDERAL
PROGRAM;12 AND

(III) PURCHASES13 AND PAYOR REIMBURSEMENTS ~~UNDER~~ BY
STATE14 FEDERAL AGENCIES OR FEDERAL PROGRAMS THAT ~~ARE~~ THE IS PREEMPTED
~~INCLUDING:~~15 FROM REGULATING BY FEDERAL LAW

~~1.~~ ~~THE~~ ~~DEPARTMENT~~ ~~DEFENSE;~~16 ~~OF~~

~~2.~~ ~~THE~~ ~~DEPARTMENT~~ ~~VETERANS~~ ~~AFFAIRS;~~17 ~~OF~~

~~3.~~ ~~THE~~ ~~PUBLIC~~ ~~HEALTH~~ ~~SERVICE;~~18

~~4.~~ ~~THE~~ ~~UNITED~~ ~~STATES~~ ~~COAST~~ ~~GUARD;~~19

~~5.~~ ~~TRICARE;~~20

~~6.~~ ~~THE~~ ~~FEDERAL~~ ~~EMPLOYEES~~ ~~HEALTH~~ ~~BENEFIT~~ ~~PLAN;~~21
22 ~~AND~~

~~7.~~ ~~ANY~~23 ~~OTHER~~ ~~EXCLUSIVE~~ ~~FEDERAL~~ ~~PROGRAM~~ ~~AS~~
~~APPLICABLE.~~24

25 SECTION 3. AND BE IT FURTHER ENACTED, That:

26 (a) Section 2 of this Act is contingent on the Prescription Drug Affordability Board
27 setting upper payment limits on two prescription drugs in accordance with § 21–2C–14 of

PAGE 14
14 HOUSE BILL 424

1 the Health – General Article, as enacted by Section 1 of this Act, and each upper payment
2 limit being in effect for 1 year.

3 (b) Within 5 days after the conditions described in subsection (a) of this section
4 are met, the Prescription Drug Affordability Board shall notify the Department of
5 Legislative Services.

6 (c) If notice is received by the Department of Legislative Services in accordance
7 with subsection (b) of this section on or before ~~September~~ ~~31~~ September 30, 2030, Section 2
8 of this Act shall take effect on the date the notice is received by the Department of
9 Legislative Services.

10 (d) If notice is not received by the Department of Legislative Services on or before
11 ~~December~~ ~~31~~ September 30, 2030, Section 2 of this Act, with no further action required by
12 the General Assembly, shall be null and void.

13 SECTION 4. AND BE IT FURTHER ENACTED, That, subject to Section 3 of this
14 Act, this Act shall take effect October 1, 2025.

Approved:

________________________________________________________________________________
Governor.

________________________________________________________________________________
Speaker of the House of Delegates.

________________________________________________________________________________
President of the Senate.